A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer

Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agents, to date, has been ascribed to either poor efficacy or hepatotoxicity. TR2/CDH3 BAB is a human bispec...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Jung, Stefan P. Glaser, Jing Han, Alexandra Popa, Laura Pisarsky, Ningping Feng, Antonia Geyer, Franziska Haderk, Donat Alpar, Christopher Bristow, Susanne Schmittner, Paula-Elena Traexler, Mikhila Mahendra, Birgit Poehn, Poojabahen Gandhi, Roberto Fiorelli, Sanket Awate, Nicole Budano, Florian Martin, Christoph Albrecht, Barbara Drobits-Handl, Sathanandam S. Anand, Srinath Kasturirangan, Francesca Trapani, Norbert Schweifer, Joseph R. Marszalek, Ulrike Tontsch-Grunt, Mark Pearson, Timothy P. Heffernan, Norbert Kraut, Christopher P. Vellano, Juan Manuel García-Martínez
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
Apoptosis
bispecific antibody
CDH3
pancreatic cancer
targeted therapy
TRAILR2
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2438173
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2024.2438173

Similar Items